Management of Growth in Pediatric Chronic Renal Failure: A Narrative Review

Background: growth impairment is a common problem in chronic kidney disease (ckd)children. approximately 40% of children with ckd have a reduced final height. growthimpairment affects school attendance, duration of hospitalization, adult height, and evenrisk of death.objectives: various studies have shown that patients with moderate to severe growth failurehave higher mortality rates (three folds) than those with normal growth. this narrativereview aimed to define the management of growth in pediatric chronic renal failure.methods: this study was conducted through a literature search with the keywords ofchronic renal failure, kidney transplant, glomerular filtration rate (gfr) combined withgrowth, short stature, and growth hormone using pubmed, scopus, web of sciences,cochrane, and embase databases.results: growth impairment in children with ckd occurs due to diverse etiologies, suchas uremia, anemia, metabolic acidosis, etc. it becomes more prominent in gfr<75 ml/min/1.73 m2. growth hormone (gh) therapy seems to be a safe and effective therapeuticmodality consequent to the correction of associated metabolic disturbances.conclusions: this study indicated that pretransplant gh therapy in children withckd and its temporary discontinuation at kidney transplantation up to one year aftertransplantation leads to improved growth velocity. therefore, it seems that consideringgh therapy in children with ckd is mandatory.